Hyundai Pharm gets South Korean rights to Aslan's cholangiocarcinoma project
Aslan Pharmaceuticals Pte. Ltd. and Hyundai Pharm Co. Ltd. will work together on the development and commercialization in South Korea of Aslan's varlitinib (ASLAN001) for cholangiocarcinoma.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.